- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01973673
Healthy Bones Study
Healthy Bones Study: An Intervention to Improve Healthy Bone Behaviours in Prostate Cancer Patients on Androgen Deprivation Therapy (ADT)
Prostate cancer patients receiving hormone treatment (androgen deprivation therapy, or ADT) are at increased risk of developing bone loss and osteoporosis as side effects. To prevent this, guidelines recommend participation in healthy bone behaviours including weight-bearing exercise and adequate calcium/vitamin D intake. However, prior studies have shown that patients are not regularly screened or counselled regarding healthy bone behaviours while receiving ADT. Maintaining bone health in prostate cancer patients is important because men on ADT are at increased risk of fractures. In this study, the investigators will examine whether an intervention designed to improve healthy bone behaviours among prostate cancer patients on ADT can be implemented. The intervention consists of a written "healthy bones prescription", brief verbal counseling, and printed educational materials for participants. Investigators hope to obtain an initial estimate of whether the intervention works. They also hope to show that this simple intervention can be implemented in a real, working cancer clinic.
The investigators hypothesize that an intervention to improve bone health in prostate cancer patients receiving ADT (healthy bones prescription, verbal counseling, and printed educational materials) is effective, implementable, and accepted by clinicians and patients.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
The study has a before-and-after design, to allow comparison of the intervention before its implementation and after its implementation. This design permits a reliable assessment of baseline characteristics prior to implementation of intervention and over time, particularly in situations where randomization is not feasible (e.g. due to contamination of treating physicians). The point at which the intervention will start to be delivered for new study participants is when 150 patients are accrued to the Before arm.
- Before/control arm (Before arm) Usual care by Princess Margaret Cancer Centre (PM) oncologist.
- After/intervention arm (After arm) Provision of a healthy bones prescription, verbal counselling, and written educational materials regarding healthy bone behaviours by PM oncologist or delegate (e.g. clinical fellow), in addition to usual care by oncologist. The intervention may be delivered again at a subsequent follow-up at the request of the patient and/or at the discretion of the oncologist.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 2M9
- Princess Margaret Cancer Centre
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
Prostate cancer patients receiving ADT at study entry (for a maximum of 12 months prior to study entry or planning to receive ADT within 3 weeks of study entry), for an expected duration of >6 months; Eastern Cooperative Oncology Group (ECOG) performance status <3
Exclusion Criteria: Unable to exercise (e.g. major physical disability, severe osteoarthritis, or other severe comorbidity); severe cardiac disease (congestive heart failure with New York Heart Association (NYHA) class >2, angioplasty/coronary artery bypass surgery within 3 months of study entry); patients with bone endocrinopathy (parathyroid disorders, osteomalacia); stage IV-V chronic kidney disease (estimated glomerular filtration rate [eGFR] <30 mL/min/1.75 m2; prior serum creatinine not required for entry into study); allergy to components of calcium & vitamin D tablets.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Støttende pleje
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Aktiv komparator: Bone health educational materials
Bone health written educational materials, Bone health prescription,verbal counselling
|
|
|
Ingen indgriben: Usual care
Usual clinical care to be provided by oncologists.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Recruitment rate
Tidsramme: 6 months
|
Proportion of eligible and consented patients who complete study follow-up, as a measure of study feasibility
|
6 months
|
|
Study completion and retention rate
Tidsramme: 3 months
|
Change in patient-reported daily calcium intake, as a measure of intervention efficacy
|
3 months
|
|
Intervention efficacy
Tidsramme: 3 months
|
Change in patient-reported weekly exercise duration, as a measure of intervention efficacy
|
3 months
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Clinical outcome
Tidsramme: 6 months
|
Proportion of patients whose calcium, vitamin D intake, and exercise may be assessed from properly completed questionnaires
|
6 months
|
|
Clinical outcome capture rate
Tidsramme: 6 months
|
Patient and clinician satisfaction with clinical study on a ten-point scale
|
6 months
|
|
Questionnaire, and Osteoporosis Health Belief Scale
Tidsramme: 3 months
|
Change in patient knowledge and health benefits regarding osteoporosis, as determined with Facts on Osteoporosis Quiz - Revised, Men's Osteoporosis Knowledge
|
3 months
|
|
BMD monitoring
Tidsramme: 6 months
|
Proportion of enrolled patients having bone mineral density (BMD) tests performed within 6 months of ADT initiation
|
6 months
|
Samarbejdspartnere og efterforskere
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: Shabbir Alibhai, MD, UHN
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 13-6050
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Lokalt avanceret malignt neoplasma
-
National Cancer Institute, NaplesRekrutteringLocally Advanced Rectal Cancer (LARC)Italien
-
Cai ZerongAfsluttet
-
Chinese PLA General HospitalIkke rekrutterer endnu
-
Beijing Bio-Targeting Therapeutics Technology Co...Trukket tilbage
-
Gruppo Oncologico Italiano di Ricerca ClinicaGlaxoSmithKlineIkke rekrutterer endnu
-
The First Affiliated Hospital of Xiamen UniversityIkke rekrutterer endnuLocally Advanced Breast Cancer (LABC)
-
Indonesia UniversityIkke rekrutterer endnuPræhabilitering | Postoperativ inflammation | Locally Advanced Breast Cancer (LABC)Indonesien
-
Atlas UniversityIkke rekrutterer endnuBrystkræft | Locally Advanced Breast Cancer (LABC)Tyrkiet (Türkiye)
-
Jiangsu Alphamab Biopharmaceuticals Co., LtdIkke rekrutterer endnuMetastatisk brystkræft | Locally Advanced Breast Cancer (LABC)Kina
-
Ontario Clinical Oncology Group (OCOG)Afsluttet
Kliniske forsøg med Bone health educational materials
-
Ziauddin UniversityUniversiti Sains MalaysiaIkke rekrutterer endnuGingivitis | TandplakPakistan
-
Cairo UniversityAfsluttetOral sygdom | Gingival sygdomEgypten
-
Duke UniversityMbarara Regional Referral Hospital; Butabika National Referral Mental HospitalIkke rekrutterer endnu
-
Cairo UniversityUkendtSundhedsholdning | Diabetes type 1
-
ElTyeb, Sara Amir Hassan, M.D.Sudan Medical Specialization Board (SMSB); Elfatih Malik, MDAfsluttetUdviklingshæmning